TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06446492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ViDEO explaining study
Description: The research team will introduce themselves and ask the parents to watch an informational video explaining the ViDES study on an iPad while they stay in the room with the parents. After viewing the video, the team will answer any questions and provide written consent and enough time to decide whether to participate in the study. The research team will also provide a QR code that grants parents/guardians access to the video on their own device at any time. This allows them to pause, rewind, and revisit the information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The research team will present a detailed explanation of the ViDES study, answer questions, provide written consent, and provide enough time to decide on participation or not in the study.
Study: NCT05552365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Cognitive Behavioural
Description: 8-session cognitive behavioural intervention adapted for children indicated to have developmental language disorder. Intervention includes psychoeducative, bodily relaxation, graded exposure, cognitive restructuring and brainstorming. Adaptations include increasing the number of visual supports, use of physical objects to illustrate concepts in addition to language.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants given a mental health brochure with contact information, where they can access services provided by mental health support service providers.
Study: NCT05538728

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: poly-l-lactic acid (Sculptra)
Description: Sculptra

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: poly-l-lactic acid (Sculptra)
Description: Sculptra
Study: NCT05701826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS3797
Description: HRS3797 for injection, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS3797
Description: HRS3797 for injection, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS3797
Description: HRS3797 for injection, medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS3797
Description: HRS3797 for injection, medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS3797
Description: HRS3797 for injection, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS3797
Description: HRS3797 for injection, high dose
Study: NCT05938686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home_Based Digital Mindful Dance Program
Description: Home_Based Digital Mindful Dance Program including warm up, dance and cool down for 60 minute with 12 weeks.
Study: NCT06149169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
Description: Relma-cel be administered at one dose level:1×10\^8 CAR+T cells
Study: NCT06271187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic-orthosis
Description: Engaging in motion training at home with the use of dynamic orthoses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional stroke occupational therapy training
Description: Traditional post-stroke movement training arranged by an occupational therapist in a medical setting.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional stroke occupational therapy training
Description: Traditional post-stroke movement training arranged by an occupational therapist in a medical setting.
Study: NCT05737979

Intervention type: OTHER
Intervention: Study chart review
Description: Evaluation of the IVF cycle using the prescribed medication
Study: NCT06184451

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic exercise
Description: The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: TENS will be applied with a portable device, Neurodyn Portable System from Ibramed, while carrying out the entire therapeutic exercise program. The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. The application time will be proportional to the time of the exercise session, approximately 60 minutes. The researcher will evaluate the need to adjust the current intensity through the pulse amplitude regularly so that the stimulus does not accommodate.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transcutaneous electrical nerve stimulation
Description: The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. To do this, the device will only be turned on during the first minute of therapeutic exercises. The same TENS parameters as the experimental group will be applied for this.
Study: NCT06673602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCYC+Conventional treatment
Description: Conventional treatment combined with oral administration of FCYC (four capsules, three times a day, orally) for a 12-week course of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: The control group will receive the current gold standard treatment for ICH according to the guidelines (AHA/ASA 2022). This involves blood pressure and care.
Study: NCT05394779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTXO APP
Description: DTXO is an investigational therapeutic intervention (Digital Therapeutics - DTx) for obese patients, under clinical validation with a randomized and placebo-controlled clinical trial for confirmatory purposes. It is intended to improve weight loss, weight-loss maintenance, and overall health in patients with obesity by increasing their self-engagement, self-monitoring and adherence to dietary/exercise and behavioral programs. The App integrates different non-pharmacological approaches, engaging the patient through monitoring of her/his non-vital parameters, monitoring of patient diet and exercise, monitoring of patient psychological status, prescription of exercise and diet in a weight-loss program.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO APP - Control group
Description: The placebo App will include only the non-medical modules of the digital therapy and has been introduced to make the experience of subjects in the control arm more similar to that of subjects in the experimental arm; moreover, data collection through the placebo app (questionnaires) will streamline the data collection process, avoiding manual data entry and reducing the possibility of entry errors.
Study: NCT04755530

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular whole milk
Description: 400 g/day of regular whole milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt with live bacteria
Description: 400 g/day of yogurt with live bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt with inactivated bacteria
Description: 400 g/day of yogurt with inactivated bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acidified whole milk
Description: 400 g/day of yogurt with acidified whole milk
Study: NCT06100705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate
Description: Testosterone Cypionate is an androgen and anabolic steroid medication which is used mainly in the treatment of low testosterone levels in men.
Study: NCT06516939

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bovine Basic Gel
Description: Bovine Basic Gel
Study: NCT04778267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Description: used as additive to bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: used as additive to bupivacaine
Study: NCT05274113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: 4 mg of Dexamethasone will be given before surgery
Study: NCT04862494

Intervention type: OTHER
Intervention: clinical surveillance
Description: regular clinical follow up including chest X-rays, pulmonary investigations, etc...
Study: NCT06100705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Sipuleucel-T is the first FDA-approved immunotherapy in treatment of mCRPC. It is a therapeutic cancer vaccine composed of activated autologous dendritic cells loaded with an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor, PAP-GMCSF, also called PA2024. This cellular product is prepared in three steps: (1) leukapheresis to isolate CD54+ dendritic cells, (2) the cells and harvested and cultured with PA2024 ex vivo, and (3) re-infusion of the activated DC into the original patient. The preparation and administration of this autologous cellular product are done every 2 weeks for a total of three infusions and is designed to elicit an immune response to prostatic acid phosphatase.
Study: NCT04862494

Intervention type: PROCEDURE
Intervention: diaphragmatic plication
Description: plication of a hemidiaphragm, performed via laparoscopy, thoracoscopy (including robot-assisted surgery), or classical thoracotomy
Study: NCT04120987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: BID OU
Study: NCT05858931

Intervention type: PROCEDURE
Intervention: vaginal repair
Description: vaginal repair
Study: NCT05774444

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: Krill oil will be supplemented to see if they can gain strength and/or muscle mass following supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: Krill oil will be supplemented to see if they can gain strength and/or muscle mass following supplementation.
Study: NCT06179264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Guide for Chronic Health Conditions
Description: Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. The current project is an online, self-guided, 6-session intervention based on ACT. The program is intended to help individuals with chronic health conditions improve their quality of life and mental health. Each session is expected to take about 30 minutes each, and the entire program will take 6 weeks to complete, as users will be encouraged to work on one session per week. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and chronic health condition specific vignettes, and apply ACT concepts to their own lives and situations related to their chronic health condition. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
Study: NCT05774444

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill protein
Description: Krill protein will be given to the participant following a resistance exercise bout.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill protein
Description: Krill protein will be given to the participant following a resistance exercise bout.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable oil
Description: This will be the control against the Krill oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetable oil
Description: This will be the control against the Krill oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate
Description: This will be the control for the Krill protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate
Description: This will be the control for the Krill protein
Study: NCT05734924

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low Frequency High Intensity magnetic therapy
Description: low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low Frequency High Intensity magnetic therapy
Description: low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT
Study: NCT04244604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Salt (sodium chloride)
Description: Varied amounts of salt (sodium chloride) will be added to a very low sodium soup to determine the effects of a single high sodium meal on measures of vascular function and autonomic regulation of blood pressure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acute Salt (sodium chloride)
Description: Varied amounts of salt (sodium chloride) will be added to a very low sodium soup to determine the effects of a single high sodium meal on measures of vascular function and autonomic regulation of blood pressure
Study: NCT06062212

Intervention type: PROCEDURE
Intervention: Transpulmonary pressure
Description: Use transpulmonary pressure to guide ventilator setting in ECMO for severe ARDS patients.
Study: NCT06447675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermic Baths
Description: The intervention will consist of 12 weeks of repeated (2x/day) 20-min body immersions.
Study: NCT05304663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onfekafusp alfa
Description: Patients will be treated with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onfekafusp alfa
Description: Patients will be treated with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Arm 1: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (60 mg/m2 and 75 mg/m2) on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~Arm 2: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (90 mg/m2 and 110 mg/m2) on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Arm 1: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (60 mg/m2 and 75 mg/m2) on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~Arm 2: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (90 mg/m2 and 110 mg/m2) on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles.
Study: NCT06134466

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Extensively hydrolyzed cow's milk protein infant formula
Description: Liquid Investigational Formula (Extensively hydrolyzed cow's milk protein infant formula) 2.8 g protein/100 kcal
Study: NCT04704037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline implementation tool
Description: Family physicians will receive a tailored letter with their patient's mental health screening test results and associated mental health treatment recommendations from the Ontario Neurotrauma Foundation guidelines, as well as a list of mental health treatment resources. In addition, the patient will receive a written information package about mental health problems after mTBI and treatment options to discuss with their family physician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Generic information about concussion management
Description: Family physicians will receive a generic letter drawing their attention to Canadian clinical practice guidelines for mild Traumatic Brain Injury (developed by the Ontario Neurotrauma Foundation). Patients will receive instructions about how to access generic education materials about mTBI (from concussion.vch.ca/), which they should have received anyway as part of usual care.
Study: NCT05573854

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gastric emptying after an oral supplement containing carbohydrates and whey protein
Description: Ingestion of an oral supplement containing carbohydrates and whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gastric emptying after an oral supplement containing carbohydrates and whey protein
Description: Ingestion of an oral supplement containing carbohydrates and whey protein
Study: NCT06557200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Infant- parents support
Description: A virtual and in-person, personal and group-based intervention will be delivered-educational information on infant behavior and changes in interpersonal dynamics associated with parenting. Modules aimed at understanding and managing infant behavior include information on infant temperament. Personal support will be provided by face-to-face education and WhatsApp messages and videos. Group support will be provided by mothers and their partners or a support person group discussion.
Study: NCT05901428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
Study: NCT05573854

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Overnight Fast
Description: Residual Gastric Volume assessed by MRI after overnight fast (8h)
Study: NCT03180450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)
Description: Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conventional treatment
Description: The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
Study: NCT04908644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-20 oral solution
Description: Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04955548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic micro-fracture with autologous adipose gel
Description: Fully cut the adipose tissue taken out under the arthroscopy, transfer the cut adipose tissue to a syringe connected with a double pass, push back and forth through the syringe to physically emulsify the adipose, and centrifuge to obtain the autologous adipose gel, and inject it into the lesion
Study: NCT05570188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 UCAR-NK cells
Description: Enrolled participants are chosen to receive one of three different dose levels of U-CAR-NK cells:~Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg.
Study: NCT04242264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sterile Normal Saline, USP
Study: NCT06491537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Eating (eTRE)
Description: 12 weeks of eTRE intervention. Study staff will provide 7 support sessions with brief behavioral support, including evidence based strategies of problem-solving, action planning, and motivational interviewing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will be instructed to maintain their average eating window for the 12-week period. Study staff will contact participants 7 times to encourage maintenance.
Study: NCT05274113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: 4 mg of Dexamethasone will be given before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ultrasound guided supraclavicular block with ropivacaine will be given to patients before surgery